Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03884712 · ClinicalTrials.gov registry record · NA
Using CalmiGo to Manage Anxiety and Panic Attack Symptoms in the Emergency Department
A NA study of Anxiety and Panic Attacks, sponsored by Yves Duroseau.
- Active
- Registry status
- NA
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT03884712: Active NA study of Anxiety and Panic Attacks, sponsored by Yves Duroseau.
NCT03884712 is a NA study of Anxiety and Panic Attacks that is active but no longer recruiting, run by Yves Duroseau. The registered enrollment target is 35 participants, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03884712, a NA study of Anxiety and Panic Attacks, is active but no longer recruiting, sponsored by Yves Duroseau.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
Currently, there are limited options in the management of anxiety and panic attack symptoms in the Emergency Department (ED). The most common treatment method is the use of anti-anxiety and anti-depressant medications; however, these drugs have serious health risks which make them ineffective as a long-term treatment option. The CalmiGo handheld device, formerly known as "myReLeaf", provides an alternative early intervention option in treating patients presenting with anxiety and panic attack symptoms by using guided breathing, aromatherapy, and grounding techniques. The hypothesis of this study is that CalmiGo will provide a drug-free, early intervention, and long-term treatment option in the ED that will improve patients' anxiety and panic attack symptoms. Patients who present to the ED with anxiety or panic attack symptoms will be considered eligible for this study. These patients will be approached, and they will give informed consent to participate in the study. Patients will be enrolled in the study which consists of completing validated surveys asking about their anxiety and panic symptoms, using CalmiGo, and allowing investigators to access their medical records. These surveys will be completed before and after using CalmiGo in the ED to measure the presence and severity of anxiety and panic symptoms. The goal of this study is to analyze the effectiveness of using CalmiGo to improve anxiety and panic attack symptoms based on validated survey responses. Overall, this study seeks to identify CalmiGo as an effective and alternative early intervention treatment option for patients presenting to the ED with anxiety or panic attack symptoms.
Primary Outcome
Panic Symptom Scale (PSS) survey responses before using CalmiGo will be compared to the PSS survey responses after using CalmiGo. The PSS rates the severity of 13 panic symptoms on a scale of 0 to 4; a rating of 0 indicates that the symptom is not present and a rating of 4 indicates that the symptom is extremely severe. The sum of all the ratings for the 13 symptoms on the PSS (raw score) represents the overall severity of the patient's panic state. A lower raw score indicates a lesser severity
Conditions Studied
Interventions
- DEVICE CalmiGo
Study Locations (1)
New York
- Lenox Hill Hospital - Manhattan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2019-08-07 |
| Est. Completion | 2025-10-01 |
| Phase | NA |
What the registry record for NCT03884712 still lists
NCT03884712 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Anxiety appearing as the primary indexed condition, and to 1 intervention - of which CalmiGo is the first listed.
NCT03884712 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03884712 about?
NCT03884712 is a clinical study titled "Using CalmiGo to Manage Anxiety and Panic Attack Symptoms in the Emergency Department". Currently, there are limited options in the management of anxiety and panic attack symptoms in the Emergency Department (ED). The most common treatment method is the use of anti-anxiety and anti-depressant medications; however, these drugs have serious health risks which make them ineffective as a l...
What is the current status of trial NCT03884712?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 35 participants. The study started on 2019-08-07. Estimated completion is 2025-10-01.
What conditions does trial NCT03884712 study?
This clinical trial studies the following conditions: Anxiety, Panic Attacks.
What interventions are being tested in trial NCT03884712?
The interventions under investigation include: CalmiGo (DEVICE).
Who is sponsoring clinical trial NCT03884712?
This trial is sponsored by Yves Duroseau, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03884712 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03884712's enrollment target sits among peer trials
35 288th of 364 higher than 73 of 364 other Anxiety trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anxiety trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Focused Ultrasound for the Complex Patient
RECRUITING · NA
-
Digital Intervention for Physical Activity
RECRUITING · NA
-
Exploring Virtual Reality Adventure Training Exergaming
RECRUITING · NA
-
Brief Interventions for Coping with Distress
RECRUITING · NA
-
Personalized Feedback Intervention for Latinx Drinkers With Anxiety
RECRUITING · NA
-
Pilot Effectiveness Trial of an ACT Self-help Workbook Tailored Specifically for Prisons
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI